These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 33278020)

  • 1. Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics.
    Koller D; Almenara S; Mejía G; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Navares-Gómez M; Santos-Molina E; Pintos-Sánchez E; Abad-Santos F
    Adv Ther; 2021 Feb; 38(2):1035-1054. PubMed ID: 33278020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial.
    Koller D; Saiz-Rodríguez M; Zubiaur P; Ochoa D; Almenara S; Román M; Romero-Palacián D; de Miguel-Cáceres A; Martín S; Navares-Gómez M; Mejía G; Wojnicz A; Abad-Santos F
    Br J Clin Pharmacol; 2020 Oct; 86(10):2051-2062. PubMed ID: 32250470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.
    Koller D; Belmonte C; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):236-246. PubMed ID: 31520576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.
    Koller D; Almenara S; Mejía G; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Wojnicz A; Martín S; Romero-Palacián D; Navares-Gómez M; Abad-Santos F
    Hum Psychopharmacol; 2021 Jan; 36(1):1-12. PubMed ID: 32991788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects.
    Koller D; Belmonte C; Lubomirov R; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Carcas A; Wojnicz A; Abad-Santos F
    J Psychopharmacol; 2018 Nov; 32(11):1212-1222. PubMed ID: 30251598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.
    Soria-Chacartegui P; Villapalos-García G; Zubiaur P; Abad-Santos F; Koller D
    Front Pharmacol; 2021; 12():711940. PubMed ID: 34335273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants.
    Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Jiang-Zheng C; Koller D; Mejía G; Zubiaur P; Wojnicz A; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):474-485. PubMed ID: 29723928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia.
    Hattori S; Suda A; Kishida I; Miyauchi M; Shiraishi Y; Fujibayashi M; Tsujita N; Ishii C; Ishii N; Moritani T; Taguri M; Hirayasu Y
    BMC Psychiatry; 2018 Jul; 18(1):231. PubMed ID: 30016952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.
    Cabaleiro T; López-Rodríguez R; Ochoa D; Román M; Novalbos J; Abad-Santos F
    Hum Psychopharmacol; 2013 May; 28(3):205-14. PubMed ID: 23559402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
    Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    Mukundan A; Faulkner G; Cohn T; Remington G
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.
    Nicol GE; Yingling MD; Flavin KS; Schweiger JA; Patterson BW; Schechtman KB; Newcomer JW
    JAMA Psychiatry; 2018 Aug; 75(8):788-796. PubMed ID: 29898210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.